MARTELLUCCI, IGNAZIO
 Distribuzione geografica
Continente #
NA - Nord America 58
EU - Europa 52
AS - Asia 19
SA - Sud America 1
Totale 130
Nazione #
US - Stati Uniti d'America 58
IT - Italia 25
JP - Giappone 10
IE - Irlanda 7
FR - Francia 5
GB - Regno Unito 5
CN - Cina 3
NL - Olanda 3
VN - Vietnam 3
SE - Svezia 2
SG - Singapore 2
CL - Cile 1
CZ - Repubblica Ceca 1
DE - Germania 1
ES - Italia 1
LU - Lussemburgo 1
RU - Federazione Russa 1
TR - Turchia 1
Totale 130
Città #
Siena 22
Santa Cruz 8
Tokyo 8
Dublin 6
Fairfield 6
Columbus 4
Philadelphia 4
Ashburn 3
Dong Ket 3
Kansas City 3
Los Angeles 3
Southend 3
Cambridge 2
Chicago 2
Houston 2
Lahontan 2
Singapore 2
Stockholm 2
Voorburg 2
Adana 1
Alicante 1
Amsterdam 1
Boiling Springs 1
Buffalo 1
Changzhou 1
Gunzenhausen 1
Ibaraki 1
London 1
Luxembourg 1
Nashville 1
Poggibonsi 1
Rhyl 1
Saint Petersburg 1
San Francisco 1
Santiago 1
Shanghai 1
Suita 1
Woodbridge 1
Totale 106
Nome #
Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients, file e0feeaa8-527c-44d2-e053-6605fe0a8db0 72
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy, file e0feeaab-b487-44d2-e053-6605fe0a8db0 39
null, file 43761f83-6f33-47d7-a34a-c12e1c320d7d 4
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer, file e0feeaa8-7a9f-44d2-e053-6605fe0a8db0 3
Head and Neck Carcinoma and biomarker profiling: searching tumor identity card., file 7ab3c356-0e23-45c9-bb97-09a07370dea2 2
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin, file e0feeaa4-dfbf-44d2-e053-6605fe0a8db0 2
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial), file e0feeaa4-e05d-44d2-e053-6605fe0a8db0 2
Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: A single-institution experience, file e0feeaa8-5ecd-44d2-e053-6605fe0a8db0 2
First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC: A real-life setting study with gender prospective, file e0feeaaa-eac0-44d2-e053-6605fe0a8db0 2
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients, file e0feeaa5-054e-44d2-e053-6605fe0a8db0 1
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients., file e0feeaa5-1213-44d2-e053-6605fe0a8db0 1
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients, file e0feeaa7-59e1-44d2-e053-6605fe0a8db0 1
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer, file e0feeaaa-55ed-44d2-e053-6605fe0a8db0 1
Totale 132
Categoria #
all - tutte 434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 434


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 1 0 0 1 0
2020/202118 0 0 0 0 1 0 2 4 1 3 2 5
2021/202227 1 4 0 1 1 1 3 0 0 1 12 3
2022/202355 5 6 7 7 6 7 0 6 3 1 7 0
2023/202428 2 0 0 1 1 5 4 2 0 3 10 0
Totale 132